Future prospects for prophylactic and therapeutic management of venous thrombosis: antithrombotic substances with lower risk of hemorrhage?
作者信息
Maffei Francisco Humberto de Abreu
机构信息
Universidade Estadual Paulista - UNESP, Faculdade de Medicina de Botucatu, Departamento de Cirurgia e Ortopedia, Botucatu, SP, Brasil.
出版信息
J Vasc Bras. 2019 May 28;18:e20190036. doi: 10.1590/1677-5449.190036.
Abstract
摘要
相似文献
1
Future prospects for prophylactic and therapeutic management of venous thrombosis: antithrombotic substances with lower risk of hemorrhage?
J Vasc Bras. 2019 May 28;18:e20190036. doi: 10.1590/1677-5449.190036.
2
Antithrombotic management and thrombosis rates in children post-liver transplantation: A case series and literature review.
Pediatr Transplant. 2019 Jun;23(4):e13420. doi: 10.1111/petr.13420. Epub 2019 Apr 23.
3
4
Antithrombotic Drugs-Pharmacology and Perspectives.
Adv Exp Med Biol. 2020;1177:101-131. doi: 10.1007/978-981-15-2517-9_4.
5
Antithrombotic action of recombinant hirudin in a venous thrombosis model.
Haemostasis. 1991;21 Suppl 1:127-32. doi: 10.1159/000216273.
6
Adherence to guidelines for perioperative management of anticoagulation results in decreased bleeding complications: a single-centre experience.
Blood Coagul Fibrinolysis. 2015 Jun;26(4):426-9. doi: 10.1097/MBC.0000000000000275.
7
Venous and arterial thrombosis in rat models: dissociation of the antithrombotic effects of glycosaminoglycans.
Blood Coagul Fibrinolysis. 2004 Jan;15(1):45-54. doi: 10.1097/00001721-200401000-00008.
8
Antithrombotic stewardship: a multidisciplinary team approach towards improving antithrombotic therapy outcomes during and after hospitalisation: a study protocol.
BMJ Open. 2016 Dec 20;6(12):e011537. doi: 10.1136/bmjopen-2016-011537.
9
The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
Thromb Haemost. 2001 Dec;86(6):1512-20.
10
[Value of a fraction of low molecular weight heparin, enoxaparine, in patients at high risk of hemorrhage and thrombosis].
Ann Med Interne (Paris). 1988;139(5):349-53.
本文引用的文献
1
Direct oral anticoagulants for treatment of deep vein thrombosis: overview of systematic reviews.
J Vasc Bras. 2018 Oct-Dec;17(4):310-317. doi: 10.1590/1677-5449.005518.
2
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.
Blood Adv. 2018 Nov 27;2(22):3257-3291. doi: 10.1182/bloodadvances.2018024893.
3
E-selectin inhibition with GMI-1271 decreases venous thrombosis without profoundly affecting tail vein bleeding in a mouse model.
Thromb Haemost. 2017 Jun 2;117(6):1171-1181. doi: 10.1160/TH16-04-0323. Epub 2017 Mar 16.
4
Can we prevent venous thrombosis with statins: an epidemiologic review into mechanism and clinical utility.
Expert Rev Hematol. 2016 Nov;9(11):1023-1030. doi: 10.1080/17474086.2016.1245137. Epub 2016 Oct 21.
5
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.
Chest. 2016 Feb;149(2):315-352. doi: 10.1016/j.chest.2015.11.026. Epub 2016 Jan 7.
6
The epidemiology of venous thromboembolism.
J Thromb Thrombolysis. 2016 Jan;41(1):3-14. doi: 10.1007/s11239-015-1311-6.
7
Pharmacology of Heparin and Related Drugs.
Pharmacol Rev. 2016 Jan;68(1):76-141. doi: 10.1124/pr.115.011247.
8
Inflammation in venous thromboembolism: Cause or consequence?
Int Immunopharmacol. 2015 Sep;28(1):655-65. doi: 10.1016/j.intimp.2015.07.044. Epub 2015 Aug 4.
9
P-selectin inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better than enoxaparin and an inhibitor to von Willebrand factor.
Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):829-37. doi: 10.1161/ATVBAHA.114.304457. Epub 2015 Feb 5.
10
The history and historical treatments of deep vein thrombosis.
J Thromb Haemost. 2013 Mar;11(3):402-11. doi: 10.1111/jth.12127.
Zotero 插件